Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. Eastern Daylight Time (EDT).


GlobeNewswire Inc | May 7, 2021 07:00AM EDT

May 07, 2021

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. Eastern Daylight Time (EDT).

The discussion will be webcast live and can be accessed at www.hutch-med.com/event. Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference, as well as during the following other conferences:

-- MS Virtual Asia Healthcare Conference from Thursday to Friday, May 13 to 14, 2021; -- Jefferies Virtual Global Healthcare Conference from Tuesday to Friday, June 1 to 4, 2021; -- Citi Pan-Asia Regional Investor Conference from Wednesday to Friday, June 2 to 4, 2021; and -- Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Friday, June 8 to 11, 2021.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMEDs filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries Mark Lee, Senior Vice +85221218200PresidentAnnie Cheng, Vice +1(973)5673786President Media Enquiries Americas ? Brad Miles, +1(917)5707340(Mobile)Solebury Trout bmiles@troutgroup.comEurope ? Ben Atwell / +442037271030 / +447771913902(Mobile) /Alex Shaw, +447779545055(Mobile)FTI Consulting HUTCHMED@fticonsulting.comAsia ? Joseph Chi Lo / +85298505033 (Mobile) / +85297836894(Mobile)Zhou Yi, HUTCHMED@brunswickgroup.comBrunswick Nominated Advisor Freddy Crossley / AthollTweedie, +44(20)78862500Panmure Gordon (UK)Limited







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC